摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid | 666260-32-8

中文名称
——
中文别名
——
英文名称
2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
英文别名
2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid;2-(3-chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid;2-(3-chloroanilino)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid
2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid化学式
CAS
666260-32-8
化学式
C12H7ClF3N3O2
mdl
——
分子量
317.655
InChiKey
FADYEGZICLBRGO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    474.0±55.0 °C(Predicted)
  • 密度:
    1.588±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    75.1
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
    申请人:GLAXO GROUP LTD
    公开号:WO2005074939A1
    公开(公告)日:2005-08-18
    Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.
    一种或多种CB2调节剂的组合,例如式(I)、(II)和(III)的化合物;以及一种或多种PDE4抑制剂对于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病,如免疫紊乱、炎症性疾病、疼痛、类风湿等症状是有用的。
  • PYRIMIDINE COMPOUND
    申请人:Matsushima Yuji
    公开号:US20110053912A1
    公开(公告)日:2011-03-03
    A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.
    一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法,基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基,例如,在2-位置具有取代基基的嘧啶-5-羧酰胺衍生物,表现出对大麻素2型受体的强效激动作用,可以成为预防和/或治疗与大麻素2型受体相关疾病,如炎症性疾病、疼痛等的药物。
  • [EN] PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS<br/>[FR] DERIVES DE PYRIMIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS CB2
    申请人:GLAXO GROUP LTD
    公开号:WO2004018433A1
    公开(公告)日:2004-03-04
    This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    这涉及到新型嘧啶生物,含有这些化合物的制药组合物,以及它们在治疗疾病中的应用,特别是疼痛,这些疾病直接或间接地由大麻素受体活性的增加或减少引起。
  • [EN] PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE PYRIMIDINE
    申请人:GLAXO GROUP LTD
    公开号:WO2004018434A1
    公开(公告)日:2004-03-04
    The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    本发明涉及新型嘧啶生物、含有这些化合物的药物组合物以及它们在治疗疾病中的应用,尤其是治疗由于大麻素受体活性的增加或减少而直接或间接引起的疼痛等疾病。
  • Pyrimidine compounds
    申请人:Eatherton John Andrew
    公开号:US20060247261A1
    公开(公告)日:2006-11-02
    The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    本发明涉及新型嘧啶生物,包含这些化合物的药物组合物以及它们在治疗疾病,特别是由于大麻素受体活性的增加或减少而直接或间接引起疾病,尤其是疼痛方面的应用。
查看更多